Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NEOGENOMICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

10/12/2021 | 05:05pm EST
Item 5.02         Departure of Directors or Certain Officers; Election of Directors;
                  Appointment of Certain Officers; Compensatory Arrangements of Certain

On October 5, 2021, Douglas M. VanOort, the former Chief Executive Officer of
NeoGenomics, Inc. (the "Company") and currently the Company's Executive Chairman
and Chairman of the Board of Directors (the "Board") of the Company, notified
the Board of his voluntary decision to retire from the Company and that in
connection with his retirement he was tendering his resignation as Executive
Chairman and Chairman of the Board of the Company, effective October 7, 2021.
Mr. VanOort will remain as a director on the Board but plans to retire as a
member of the Board before the end of the year as the Board concludes an ongoing
search process. Mr. VanOort's decision to retire and resign as Executive
Chairman and Chairman of the Board was not the result of any dispute or
disagreement with the Company, the Company's management or the Board on any
matter relating to the operations, policies or practices of the Company.
On October 5, 2021, the Board acknowledged Mr. VanOort's decision to retire,
accepted Mr. VanOort's resignation as Executive Chairman and Chairman of the
Board of the Company effective October 7, 2021, and appointed Lynn A. Tetrault,
the Company's Lead Independent Director, as the non-executive Chair of the
Board, effective October 7, 2021. Ms. Tetrault has served as Lead Independent
Director of the Board since July 2020 and has been on the Board since June 2015.
The Board also approved Ms. Tetrault to receive an additional quarterly fee of
$15,625, and an equity grant in the amount of $50,000 for serving as Chair of
the Board.
Following the effective date of his resignation as Executive Chairman and
Chairman of the Board, Mr. VanOort's compensation as a director is consistent
with the compensation of other directors as described in the Company's Proxy
Statement on Schedule 14A for the Company's 2021 Annual Meeting of Stockholders,
which was filed with the SEC on April 15, 2021.
Item 7.01   Regulation FD Disclosure.

On October 12, 2021, the Company issued a press release announcing Mr. VanOort's retirement as the Company's Executive Chairman and Chairman of the Board of Directors and the appointment of Lynn Tetrault as the new Non-executive Chair of the Board, the entire text of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.               Description

99.1                        Press Release of NeoGenomics, Inc. dated October 1    2    , 2021.
104                       Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

All news about NEOGENOMICS, INC.
11/30NEOGENOMICS : To Participate In The Stephens Annual Investment Conference 2021
11/29INSIDER SELL : Neogenomics
11/10NEOGENOMICS INC : Change in Directors or Principal Officers (form 8-K)
11/10NeoGenomics, Inc. Appoints William Bonello as Chief Financial Officer, Effective Januar..
11/10NeoGenomics, Inc. Appoints Kathryn Mckenzie as Chief Sustainability and Risk Officer, E..
11/10NeoGenomics, Inc. Appoints Dave Daly to Its Board of Directors
11/10NeoGenomics Appoints Dave Daly to Its Board of Directors
11/08Morgan Stanley Cuts NeoGenomics to Equal-Weight From Overweight, Price Target to $45 Fr..
11/08Genetron Holdings, NeoGenomics to Collaborate to Provide China-Based Medical Research S..
11/08Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Onco..
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 485 M - -
Net income 2021 0,67 M - -
Net Debt 2021 288 M - -
P/E ratio 2021 -9 156x
Yield 2021 -
Capitalization 3 754 M 3 754 M -
EV / Sales 2021 8,34x
EV / Sales 2022 7,20x
Nbr of Employees 1 700
Free-Float 96,0%
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 11
Last Close Price 30,49 $
Average target price 51,70 $
Spread / Average Target 69,6%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors